Financials data is unavailable for this security.
View more
Year on year NRX Pharmaceuticals Inc had revenues remain flat at 0.00, though the company grew net income from a loss of 39.75m to a smaller loss of 30.15m.
Gross margin | -- |
---|---|
Net profit margin | -- |
Operating margin | -- |
Return on assets | -231.96% |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in USDView more
In 2023, cash reserves at NRX Pharmaceuticals Inc fell by 15.46m. Cash Flow from Financing totalled 6.20m or -- of revenues. In addition the company used 21.66m for operations while cash used for investing totalled 3.00k.
Cash flow per share | -0.7339 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -1.65 |
---|---|
Tangible book value per share | -1.65 |
More ▼
Balance sheet in USDView more
Current ratio | 0.2023 |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 93.41%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | 61.95 |